News

During a live event, Steven I. Robinson, MBBS, discussed guideline-concordant active surveillance and systemic therapies for managing desmoid tumors.

New NCCN guidelines recommend lurbinectedin with atezolizumab as a first-line maintenance therapy for extensive-stage small cell lung cancer, enhancing treatment options.

Dr Daniel Petrylak discusses groundbreaking advancements in prostate cancer treatment, including genetic mutations, PARP inhibitors, and innovative PROTAC therapies.

A machine learning model enhances treatment decisions for hepatocellular carcinoma, optimizing survival outcomes through personalized risk stratification.

Innovative treatments like JAK2 inhibitors and bispecific antibodies show promise in overcoming immunotherapy resistance in non-small cell lung cancer.

Innovative CAR-iNKT cell therapy shows promise in improving outcomes for acute myeloid leukemia, offering cost-effective and potent treatment options.

Discover the latest breakthroughs in oncology, including FDA designations and promising therapies for ovarian, breast, head and neck, bladder, and renal cancers.

Physicians enhance patient care through intentional listening, fostering trust, and connection while combating burnout and improving communication in healthcare.

During a live event, Misty D. Shields, MD, PhD, discusses how trilaciclib reduces myelosuppression and other complications in small cell lung cancer.

MNV-201 gains FDA fast track designation for myelodysplastic syndromes, promising expedited development and potential breakthroughs in treatment.

Larotrectinib shows promising efficacy and safety as a first-line treatment for TRK fusion cancer in both adults and children.

Replimune navigates FDA challenges for RP1, an innovative melanoma treatment, while emphasizing the urgent need for effective therapies in advanced cases.

A new treatment combination shows promise in extending progression-free survival for advanced prostate cancer patients, highlighting innovative cancer therapies.

A novel combination therapy shows promising results in metastatic colorectal cancer, offering improved response rates and survival compared to existing treatments.

During a live event, Taha Al-Juhaishi, MD, discussed long-term outcomes of treating blastic plasmacytoid dendritic cell neoplasm and how to navigate toxicities and transplant.

A new study reveals that combining vitrectomy and silicone oil with plaque brachytherapy may enhance survival rates in uveal melanoma patients.

New study reveals plixorafenib shows significant clinical benefits for thyroid cancer patients with BRAF mutations, offering hope for targeted therapies.

New data from the THIO-101 trial shows ateganosine combined with cemiplimab significantly improves progression-free survival in advanced lung cancer patients.

Jason S. Starr, DO, discusses the CABINET trial of cabozantinib in pancreatic neuroendocrine tumors.

The FDA approved Bosaya and Aukelso biosimilars, enhancing options for cancer-related bone loss, including in patients with multiple myeloma.

The FDA fast-tracks CRB-701, an innovative ADC for advanced head and neck cancer, showing promising efficacy and safety in ongoing trials.

A new trial reveals PTCy and abatacept significantly reduce chronic GVHD in stem cell transplant patients, offering promising outcomes over standard care.

During a live event, Raajit K. Rampal, MD, PhD, discussed ropeginterferon's potential to reduce JAK2 allele burden in low-risk polycythemia vera.

During a live event, Kit Yu Lu, MD, discussed data on antibody-drug conjugates in HR+, HER2- breast cancer including the TROPION-Breast01 trial. This is the second of 2 parts from this event.

Ligufalimab receives FDA orphan drug designation for AML, showcasing promising efficacy and safety in treating hematologic malignancies and solid tumors.

A study reveals significant survival disparities in plasma cell leukemia, highlighting the benefits of stem cell transplantation for patient outcomes.

During a live event, Tian Zhang, MD, MHS, discussed darolutamide in mHSPC, with efficacy and cost being key considerations for treatment selection.

During a live event, Shirish M. Gadgeel, MD, discussed different management approaches to the improve tolerability of amivantamab/lazertinib in EGFR-mutated lung cancer.